Skip to main content
. 2014 Sep;21(9):1323–1329. doi: 10.1128/CVI.00370-14

FIG 5.

FIG 5

Complement deposition using C1q-depleted sera supplemented with rFicolin-2 lysine-57 mutants. Shown is deposition of C4 (left) and C3 (right) on serotypes 11D (wcjE containing) (A) and 11Dx (wcjE null) (B) in 5% C1q-depleted serum following opsonization with medium control, wild-type rFicolin-2 (WT rFicolin-2), or mutant rFicolin-2 (K57E or K57R) in the absence or presence of inhibitors acBSA (10 mg/liter) and BSA (10 mg/liter).